This morning, Imperus Technologies announced it had reached an agreement with PokerStars to integrate certain Akamon slot games into Jackpot Poker.
“Players have told us they want the ability to play slots while enjoying our jackpot tournaments and cash games,” said Lloyd Melnick, director of social at PokerStars. “The addition of Akamon’s slots to Jackpot Poker by PokerStars is the next evolution of Jackpot Poker, and we will continue to add the features and capabilities our players want.”
Garcea says the scope of the agreement should be a boost to Imperus.
“The distribution agreement will integrate a selection of the best Akamon social slot games onto ‘Jackpot Poker by PokerStars’, a free-to-play mobile poker app,” notes the analyst. “Akamon games reach a potential audience of over 500M users through its various distribution channels; 76% are gaming sites, 12% are telecoms (Orange, Starmedia, UOL), and 12% other media. The set of social slots to be initially provided are ‘Fire Wheel7s’, ‘Monte Carlo’, and ‘Salsa Nights’.”
In a research update to clients today, Garcea maintained his “Buy (Speculative) rating and one-year price target of $0.50 on Imperus Technologies, implying a return of 426 per cent at the time of publication.
OpenText (OpenText Stock Quote, Chart, News, Analysts, Financials NASDAQ:OTEX) reported fiscal second-quarter results on Feb. 5 that RBC Capital Markets… [Read More]
ATB Capital Markets analyst Martin Toner maintained a “Sector Perform” rating on Lightspeed Commerce (Lightspeed Commerce Stock Quote, Chart, News,… [Read More]
Roth Capital Markets analyst Darren Aftahi reiterated a “Buy” rating and US$94.00 12-month price target on IREN Limited (IREN Limited… [Read More]
Roth Capital Markets analyst Rohit Kulkarni reiterated a “Neutral” rating on Snap (Snap Stock Quote, Chart, News, Analysts, Financials NYSE:SNAP)… [Read More]
Desjardins Securities analyst Brent Stadler expects “another vanilla quarter” from Algonquin Power (Algonquin Power Stock Quote, Chart, News, Analysts, Financials… [Read More]
Research Capital analyst Andre Greg McLeish reiterated a “Buy” rating and $3.50 price target on Cannara Biotech (Cannara Stock Quote,… [Read More]